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To date, delivery of neurotrophic factors has only allowed to
transiently protect axotomized facial motoneurons against cell
death. In the present report, long-term protection of these neu-
rons was evaluated by continuously expressing the neurotrophic
factor glial cell line-derived neurotrophic factor (GDNF) within the
facial nucleus using a lentiviral vector system. The viral vector
was injected unilaterally into the facial nucleus of 4-month-old
Balb/C mice. In contrast to axotomy in other adult rodents, facial
nerve lesion in these animals leads to a progressive and sus-
tained loss and/or atrophy of .50% of the motoneurons. This
model thus represents an attractive model to evaluate potential
protective effects of neurotrophic factors for adult-onset mo-
toneuron diseases, such as amyotrophic lateral sclerosis. One
month after unilateral lentiviral vector injection, the facial nerve
was sectioned, and the animals were killed 3 months later. Viral
delivery of the GDNF gene led to long-term expression and
extensive diffusion of GDNF within the brainstem. In addition,
axotomized motoneurons were completely protected against cell
death, because 95% of the motoneurons were present as dem-
onstrated by both Nissl staining and choline acetyltransferase
immunoreactivity. Furthermore, GDNF prevented lesion-induced
neuronal atrophy and maintained proximal motoneuron axons,
despite the absence of target cell reinnervation. This is the first
evidence that viral-mediated delivery of GDNF close to the mo-
toneuron cell bodies of the facial nucleus of adult mice can lead
to complete and long-term protection against lesion-induced cell
death.
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Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegen-
erative disorder characterized by the loss of motoneurons leading
to progressive paralysis and death within 2–5 years. With the
exception of mutations in the gene for superoxide dismutase I
(SOD) found in ;2% of all cases (Rosen, 1993), the etiology of the
disease is still unknown and no treatment is currently available. A
number of animal models, such as facial or sciatic nerve axotomy in
neonatal rodents, have been developed to evaluate potential pro-
tective effects of neurotrophic factors (Sendtner et al., 1990; Koli-
atsos et al., 1993; Henderson et al., 1994; Zurn et al., 1994; Yan et
al., 1995). However, axotomy in neonates leads to a rapid cell death
(4–5 d) (Snider et al., 1992), whereas degeneration is progressive
and extends over several months in ALS. Second, ALS is an
adult-onset motoneuron disease, and mature motoneurons may be
less dependent on trophic support than developing neurons (Pollin
et al., 1991). In the present report, motoneuron axotomy was
performed in adult Balb/C mice because, in contrast to axotomy in
other adult rodents, facial nerve lesion in these animals leads to a
progressive and long-term loss of motoneurons (Kou et al., 1995;
Ferri et al., 1998). This relatively slow cell death more closely
resembles the degeneration observed in motoneuron diseases be-
cause it extends over a period of several weeks (Kou et al., 1995).
It thus represents a better model than axotomy in neonatal animals
to evaluate potential protective effects of neurotrophic factors for
adult-onset motoneuron disorders. Spinal root avulsion, another
adult lesion model, is less appropriate because not only motoneu-
ron loss but also complete loss of associated Schwann cells occurs
(Koliatsos et al., 1994).
To date, delivery of recombinant neurotrophic factors close to
the cut nerve in neonatal rats and mice has only allowed to
transiently protect axotomized motoneurons against cell death
(Schmalbruch and Rosenthal, 1995; Vejsada et al., 1995). Long-
term protection against degeneration is therefore still a major
unresolved issue. To obviate this problem, adenoviral vectors have
been used to deliver neurotrophic factors to the cut nerve stump of
lesioned motoneurons. However, ,10% of the motoneurons retro-
gradely transported and expressed the transgenes, and only a
partial rescue was observed (Baumgartner and Shine, 1997; Gime-
nez y Ribotta et al., 1997; Gravel et al., 1997). We therefore
assessed whether continuous expression of glial cell line-derived
neurotrophic factor (GDNF) in the vicinity of the motoneuron cell
bodies of the facial nucleus would allow efficient and sustained
protection against cell death. GDNF was chosen because it is the
most potent neurotrophic factor for cultured embryonic motoneu-
rons described to date (Henderson et al., 1994), as well as the most
efficient factor to rescue axotomized neonatal motoneurons when
delivered close to the nerve stump (Yan et al., 1995; Vejsada et al.,
1998). A lentiviral (human immunodeficiency virus)-based vector
system was used to deliver GDNF directly into the brain. The core
particles of this vector system are pseudotyped with vesicular
stomatitis virus glycoprotein G, which confers a broad tropism and
allows to infect a large variety of different cell types (Naldini et al.,
1996b). Moreover, the vector has been shown to transduce both
dividing and nondividing cells such as neurons and to integrate
transgenes into the chromosomes of their targets, resulting in the
long-term expression of the transgene. This efficient gene delivery
system has been applied previously in vivo in the brain of rats and
monkeys (Naldini et al., 1996a; Zufferey et al., 1997; Kordower et
al., 1999; De´glon et al., 2000).
MATERIALS AND METHODS
Production of recombinant lentiviral vectors. The cDNA coding for a
nuclear-localized b-galactosidase (LacZ), the human GDNF containing a
Kozak consensus sequence (a 636 bp fragment, position 1–151 and 1–485;
GenBank accession numbers L19062 and L19063), or a mutated GDNF
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(deletion of amino acids 74–85 of the mature GDNF, leading to the
absence of secretion of the trophic factor) (Choi-Lundberg et al., 1997)
were cloned in the SIN-W-PGK transfer vector (De´glon et al., 2000). The
packaging construct used in this study was the pCMVDR-8.92 (derived
from the pCMVDR-8.91plasmid: destruction of the BamHI restriction site
in the coding region of the rev gene). To further decrease the risk of
recombination and production of replication-competent retroviruses, the
Rev gene was inserted in the pRSV-Rev plasmid. The viral particles were
pseudotyped with the vesicular stomatitis virus G-protein encoded by the
pMD.G plasmids described previously (Naldini et al., 1996b). The viral
particles were produced by transient transfection of 293T cells (Naldini et
al., 1996b). Forty-eight hours later, the supernatant was collected and
filtered, and the particle content was determined by ELISA assay (NEN,
Boston, MA). High-titer stocks were obtained by ultracentrifugation. The
pellet was resuspended in PBS and 1% BSA and stored frozen at 280°C.
The batches of virus were tested for the absence of replication-competent
viral vectors (Naldini et al., 1996b). The titers of the lentiviral vector
encoding LacZ (LV-LacZ) stocks were determined on 293T cells. The
cells were plated at a density of 2 3 10 5 cells per well on six-well tissue
culture dishes (Costar, Cambridge, MA). Serial dilutions of the viral
stocks were added, and the number of LacZ-infected cells was analyzed 48
hr later. Titers were calculated by counting the number of blue foci per well
and dividing it by the dilution factor. LacZ-expressing viruses with ranges
from 3 to 7 3 10 8 transfection units/ml were obtained. In all in vivo
experiments, LacZ, GDNF, or mutated GDNF-expressing virsuses (LV-
LacZ, LV-GDNF, and LV-mGDNF, respectively) were matched for par-
ticle content (200,000 ng p24 antigen/ml as measured by ELISA assay).
These experiments were performed in biosafety level 2 laboratories.
Animals and surgery. Adult BalB/C mice (4 months old; IFFA Credo,
Reims, France) were anesthetized with an intraperitoneal injection of 60
mg/kg pentobarbital and placed in a stereotaxic frame (David Kopf
Instruments, Tujunga, CA). The experiments were performed in accor-
dance with the European Community Council Directive (86/609/EEC) for
care and use of laboratory animals. A midline incision was performed on
the skin covering the skull, and the bregma point was determined. The
skull was opened with a dental drill at a location 6.2 mm caudal and 1.2 mm
lateral to the bregma, the coordinates for the facial nucleus. One microliter
of lentiviral vector expressing either GDNF, mutated GDNF, or the
reporter gene LacZ was injected at the rate of 0.2 ml /min down to a depth
of 5.6 mm. Other control groups consisted of animals that received either
a 1 ml PBS solution at the same coordinates or no treatment. Thirty days
later, the animals were anesthetized with pentobarbital. The skin was
incised below the right ear. The right facial nerve was exposed, freed of
connective tissue, and transected at its exit from the stylomastoı¨d foramen.
A small segment of the nerve was removed to prevent regeneration. The
skin incision was sutured with a Prolene 6–0 filament (Johnson & John-
son). The success of the procedure was confirmed by the absence of
movement of the whiskers on the side of the lesion. The animals were then
returned to their cages and maintained in a P2 facility. They were killed 30
or 90 d later by an overdose of pentobarbital and perfused under RNase-
free condition with PBS, followed by a 4% paraformaldehyde solution.
Thereafter, the brainstem was removed and post-fixed in the same fixative
overnight and cryoprotected in PBS containing 25% sucrose. Frozen
sections of the brainstem (20-mm-thick) were cut on a Reichert Jung
Cryocut 1800 at 224°C.
Immunohistochemistry. Brainstem sections from animals injected with
LV-LacZ were processed for b-galactosidase immunoreactivity and double
stained for glial fibrillary acidic protein (GFAP) or SMI-32, an antibody
recognizing nonphosphorylated neurofilament protein used to identify
motoneurons and their central processes. Free-floating sections were
blocked in a solution containing 10% normal goat serum and 0.1% Triton
X-100 in PBS for 3 hr. The following primary antibodies were used: rabbit
polyclonal anti-b-galactosidase, 1:500 (5 Prime 3 3 Prime Inc., Boulder,
CO), mouse monoclonal anti-GFAP, 1:50 (Boehringer Mannheim, Mann-
heim, Germany), and mouse anti-SMI-32, 1:4000 (Sternberger Mono-
clonals, Lutherville, MD). Primary antibodies were diluted in the blocking
solution, and sections were incubated overnight at 4°C. Sections were then
incubated for 3 hr with the secondary goat anti-mouse Cy3-conjugated
antibody at a 1:400 dilution and goat anti-rabbit FITC-conjugated antibody
at a 1:100 dilution in PBS (Jackson ImmunoResearch, West Grove, PA).
Finally, sections were mounted onto glass slides and coverslipped using
Fluorosave (Calbiochem, La Jolla, CA). For choline acetyltransferase
(ChAT) immunohistochemistry, sections were washed in PBS and incu-
bated in 10% normal goat serum for 2 hr, followed by an overnight
incubation at 4°C with a monoclonal ChAT antibody at a 1:400 dilution
(generous gift of Dr. Cozzari, Istituto di Biologia Cellulare, Roma, Italy)
(Umbriaco et al., 1994). Control sections were incubated without the
primary antibody. After incubation with the secondary antibody, binding
was detected using an Elite avidin-biotin-peroxidase kit (Vector Labora-
tories, Burlingame, CA). To evaluate diffusion of GDNF in the brainstem,
immunohistochemistry using an anti-human GDNF antibody was per-
formed. Briefly, 20-mm-thick sections were first quenched for 20 min in 0.1
M sodium periodate, followed by a 1 hr blocking in 100 mM Tris/150 mM
NaCl (TBS) containing 2% BSA, 3% normal horse serum (NHS), and
0.5% Triton X-100. They were then incubated for 48 hr at room temper-
ature in TBS containing biotinylated goat anti-GDNF antibody (R & D
Systems, Wiesbaden, Germany) at a 1:250 dilution, 1% BSA, 1% NHS, and
0.04%Triton X-100. The sections were then incubated for 1 hr at room
temperature in the same buffer containing biotinylated horse anti-goat IgG
(1:200) (Vector Laboratories), 1% NHS, and 1% BSA. Antibody binding
was revealed according to standard procedures using an Elite avidin-
biotin-peroxidase kit (Vector Laboratories) and DAB.
In situ hybridization. To confirm the expression of the transgene close to
the facial nucleus, in situ hybridization was performed with a woodchuck
hepatitis virus (WHV) digoxigenin (DIG) riboprobe. The WHV regula-
tory element is present on all lentiviral constructs used in this study
(De´glon et al., 2000). A 591 bp fragment of the WHV post-transcriptional
element (position 1093–1684 of the WHV complete genome; GenBank
accession number J04514) was cloned in the pBluescript SK 1 plasmid
(Stratagene, La Jolla, CA). The antisense riboprobe was synthesized from
a BamHI linearized pBluescript-WHV vector according to the supplier’s
manual (DIG RNA labeling kit; Roche Products, Rotkreuz, Switzerland).
The concentration of the digoxigenin-11 UTP- labeled probe was mea-
sured by dot blot using a DIG-labeled control RNA as internal standard.
Frozen brain tissue obtained as described above was embedded in RNase-
free Tissue Tek OCT Compound (Bayer, Zurich, Switzerland) and 20 mm
sections were cut at 224°C using a cryostat. Free-floating sections were
washed in 0.1% DEPC in PBS twice for 15 min, treated with HCl 0.02 N
for 10 min, and equilibrated in 53 SSC (0.75 mM NaCl and 0.075 mM Na3
citrate) for 15 min. The sections were then prehybridized in 50% form-
amide, 53 SSC, 5% dextran sulfate, 13 Denhardt’s solution (1% bovine
serum albumin, 1% polyvinylpyrrolidone, and 1% Ficoll 400), 250 mg/ml
heat-denatured sheared salmon sperm DNA, and 100 mg/ml yeast t-RNA
for 2 hr at 48°C. Hybridization was performed overnight at 48°C with the
DIG riboprobe in the prehybridization buffer. Sections were then washed
in 23 SSC for 30 min at room temperature, followed by 23 SSC for 1 hr
and 0.13 SSC for 1 hr at 48°C. The hybridized DIG riboprobe was revealed
as described by the manufacturer (Boehringer Mannheim).
GDNF ELISA assay. To evaluate the level of GDNF expression in the
brainstem, 4-month-old Balb/C mice received intrafacial nucleus injections
of either 1 ml of lentivirus carrying the GDNF or LacZ gene, or the carrier
solution PBS (see below). Sixty days later, the animals were killed with an
overdose of pentobarbital and perfused with an ice-cold solution of PBS
containing 0.2% ascorbic acid. The brainstem was immediately removed
and frozen at 270°C on dry ice. It was then cut in the midline and
resuspended in 500 ml of PBS containing 0.5% Triton X-100 and protease
inhibitors [chymotrypsin, papain, pronase, thermolysin, and trypsin (Com-
plete Protease Inhibitor; Boehringer Mannheim)]. The proteins were ex-
tracted by sonication and centrifuged at 10,000 rpm for 10 min. The
supernatants were frozen to 270°C before further use. The amount of
human GDNF present in the sample was determined using an ELISA assay
(Promega, Madison, WI). Because of the low recovery rate of GDNF from
mouse brain, an internal standard curve was performed by adding increas-
ing doses of recombinant human GDNF to brainstem tissue of control
mice before extraction.
Motoneuron counts. To evaluate the number of motoneurons in the facial
nucleus, adjacent sections stained for Nissl, and ChAT and SMI-32 immu-
noreactivity, were counted in every fifth section on both the lesioned and
control sides. Motoneuron survival was expressed as the percentage of
cells surviving on the lesioned side compared with the nonlesioned side.
With Nissl staining, only neurons with clearly visible nucleoli and a large
soma diameter (;20 mm) were counted. All ChAT-immunopositive cells
were counted. SMI-32-positive cells were counted as motoneurons when
they presented a large soma diameter. The number of cells expressing the
GDNF construct was evaluated by in situ hybridization for the WHV
post-transcriptional enhancer element in randomly selected animals.
Motoneuron soma size. Motoneuron soma size was measured by digitiz-
ing the most central section of the facial nucleus of all animals in each
group (;350 cells per group) with a Panasonic CCD camera and by
drawing the perimeter of each motoneuron at a magnification of 2003.
Results were analyzed using NIH Image software (version 1.47).
Statistical analysis. All data were expressed as the mean 6 SEM. For
statistical evaluation of motoneuron numbers identified by either Nissl
staining or ChAT immunoreactivity, the number of cells present in each
facial nucleus was counted, multiplied by five (every fifth section was
counted), and then multiplied by the Abercrombie correction factor, which
compensates for double counting in adjacent sections (Abercrombie,
1946). Standard one-way ANOVA followed by a Scheffe’s PLSD post hoc
test was performed using the statistical software Statview 4.0. Statistical
analyses of the square areas of the cell bodies were performed using
one-way ANOVA followed by a Scheffe’s PLSD post hoc test.
RESULTS
Transgene expression in unlesioned animals
b-galactosidase expression
Two months after LV-LacZ injection, b-galactosidase was found to
be expressed in 20,595 6 2737 cells (n 5 4) in brainstem sections
of nonlesioned animals. Labeling was observed over a rostrocaudal
and lateral distance of 2.5 6 0.13 and 0.9 6 0.11 mm (n 5 4),
respectively, including the whole extent of the facial nucleus
(Fig. 1). Long-term expression of the transgene was confirmed by
5588 J. Neurosci., August 1, 2000, 20(15):5587–5593 Hottinger et al. • Motoneuron Rescue by GDNF Expression in the Facial Nucleus
the presence of 24,213 6 3130 (n 5 4) b-galactosidase-positive cells
4 months after the injection. Because of the small size and the
location of the facial nucleus, the injection needle could be placed
within the facial nucleus itself in approximately half of the cases, as
evidenced by the localization of the needle tract by Nissl staining.
In the latter case, 6293 6 753 (n 5 2) cells were infected within the
facial nucleus itself. Double-labeling with anti-SMI-32 antibodies
(used as a marker for motoneurons) showed that 35 6 7.7%
(n 5 2) of the motoneurons expressed b-galactosidase. When the
injection was performed above the nucleus, 10.9 6 5.1% (n 5 2)
of the SMI-32-positive motoneurons were labeled. Using the
glial cell marker GFAP, 17.27 6 1.2% (n 5 4) of the infected
cells were found to be astrocytes.
Localization of the GDNF construct
The GDNF construct itself was localized by in situ hybridization
for the post-transcriptional enhancer element of the WHV (Fig. 2).
Sixty days after viral infection, the mRNA was found to be present
in 17,045 6 981 (n 5 4) cells covering a distance of 2.4 6 0.2 mm
rostrocaudally. In the cases in which the injection was directly
within the facial nucleus, 41.6 6 2.1% (n 5 3) of the motoneurons
expressed the transgene, as verified on adjacent Nissl-stained
sections.
GDNF expression and diffusion
In vitro infection of 293T cells with LV-GDNF allows the synthesis
and secretion of 319 6 46 ng GDNF/106 cells per day, as assayed
by ELISA (De´glon et al., 2000). In addition, the released GDNF is
bioactive because it increases ChAT activity twofold to threefold in
embryonic day 14 spinal cord cultures (De´glon et al., 2000). Infec-
tion with LV-mGDNF resulted in no detectable GDNF produc-
tion. An ELISA assay for GDNF was performed 60 d after viral
infection on brainstem tissue punches of 0.8 mm diameter and 2
mm depth. Mice that had received injections of LV-GDNF ex-
pressed 1.69 6 0.51 ng of GDNF per punch (n 5 4), whereas
GDNF levels were below the detection limit on the uninjected side
or in control animals that had received LV-LacZ (n 5 4). To assess
long-term expression of GDNF in and around the facial nucleus,
GDNF production and diffusion were evaluated by immunohisto-
chemistry. The micrograph in Figure 3 reveals that GDNF diffused
over long distances, beyond the location of the transduced cells
(Fig. 2).
Protective effects of GDNF in lesioned animals
Facial nerve axotomy in 5-month-old Balb/C mice led to a severe
loss of motoneurons, with only 40.2 6 2.1 (n 5 4) and 46.3 6 2.5%
(n 5 6) of the neurons surviving compared with the nonlesioned
side 30 and 90 d after the lesion, respectively (no statistical differ-
ence between these two groups; p . 0.1) (Fig. 4A,B, Nissl stain-
ing). Note that motoneuron loss does not seem to occur naturally in
these mice with age, because 2947 6 30 and 2929 6 200 (n 5 4)
facial motoneurons were present at 2 and 8 months of age, respec-
tively, and because ChAT levels were also stable with age (data not
shown). Injection of PBS, LV-LacZ, or LV-mGDNF had no
significant effect on cell loss, with 44.95 6 0.8 (n 5 4), 51.8 6 7.2
(n 5 4), and 44 6 6.6% (n 5 6) of the motoneurons remaining after
30 d, respectively (Fig. 4A) (no statistical difference between these
groups and untreated animals). Similar results were obtained in the
different control groups 90 d after the lesion (Fig. 4B). In contrast,
animals pretreated with LV-GDNF showed a complete rescue of
the axotomized motoneurons, with 109.4 6 4.3 (n 5 7, p , 0.0001)
and 95 6 4.9% (n 5 8, p , 0.0001) of the cells remaining after 30
and 90 d, respectively (Fig. 4A,B). Evaluation of the number of
ChAT-positive cells 30 d after the lesion showed that only 26.2 6
4.8 (n 5 4) and 23.7 6 8.9% (n 5 4) of the cells were present in
PBS- and LV-mGDNF-treated animals, respectively, whereas in
the presence of GDNF, 77.9 6 6.1% of the cells expressed ChAT
Figure 1. b-galactosidase expression in the
brainstem of nonlesioned mice 60 d after the
injection of LV-LacZ. The number of
b-galactosidase-positive cells per 20 mm section
was evaluated every 100 mm over a rostrocaudal
distance of 3 mm. The center of the facial nu-
cleus was determined and used as a reference
point in the four animals (number of cells per
section 6 SEM).
Figure 2. In situ hybridization for the WHV element. A, Nonlesioned mice
60 d after LV-GDNF injection in the facial nucleus. The region of the facial
nucleus is indicated by small dots. Scale bar, 500 mm. B, Close-up view
showing motoneurons in the facial nucleus (arrows) and other infected cells.
Scale bar, 100 mm.
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(n 5 4, p , 0.001) (Fig. 4C). Protective effects were sustained for
several months, with 95.3 6 2.5% (n 5 8) of the cells expressing
ChAT at 3 months in the presence of GDNF but only 29.9 6 5.2
(n 5 6), 35.4 6 5.2 (n 5 6), 38.37 6 6.7 (n 5 6), and 45.5 6 4.5%
(n 5 6) in animals treated with LV-LacZ, LV-mGDNF, PBS, or no
treatment, respectively (Fig. 4D). Photomicrographs of Nissl- and
ChAT-stained sections 3 months after the lesion are shown in
Figures 5 and 6, respectively. Importantly, not only cell bodies but
also central processes were maintained in the brainstem in the
presence of GDNF, as evidenced by immunostaining with anti-
neurofilament antibody (Fig. 7). (Note that SMI-32 does not dis-
tinguish between axons and dendrites.) Thus, motoneuron cell
bodies as well as proximal processes were present with GDNF
despite the absence of target cell reinnervation, as evidenced by the
absence of whisker movement.
Assessment of the distribution of motoneuron soma sizes on the
lesioned and the nonlesioned side showed that there was a decrease
in the percentage of cells in the 400–500 mm2 size and an increase
in the 250–350 mm2 size 3 months after axotomy (Fig. 8A–E). This
indicates that, in addition to cell loss, there is also atrophy in
neurons remaining after the lesion. Furthermore, there is an in-
crease in the percentage of cells in the 400–700 mm2 size in the
presence of GDNF on the lesioned but also on the nonlesioned side
(Fig. 8C,F), indicating hypertrophy induced by the neurotrophic
factor. Similar changes were observed at 1 month. Continuous
expression of GDNF in the facial nucleus region induced a sus-
tained weight loss starting day 3 after injection and reaching 31.2 6
2.4% (n 5 8) loss at 40 d, which it maintained for 4 months. Despite
this important loss and a 27.3 6 3.1% (n 5 8) decrease in food
intake, these animals have unchanged activity levels as evaluated
using a monitoring box (data not shown).
DISCUSSION
The present report demonstrates that, using facial nerve lesion in
adult Balb/C mice, expression of the neurotrophic factor GDNF
close to the motoneuron cell bodies of the facial nucleus using a
lentiviral vector system leads to extensive diffusion of GDNF in the
brainstem and to a complete and sustained protection against
lesion-induced cell death.
Infection of the brainstem with a lentiviral vector encoding the
reporter gene LacZ leads to b-galactosidase expression in .20,000
cells within and surrounding the facial nucleus. A comparable
Figure 3. Immunodetection of GDNF in the brainstem. A, GDNF immu-
noreactivity 4 months after injection of LV-GDNF close to the facial
nucleus. The region of the facial nucleus is indicated by small dots. Animals
injected with LV-LacZ (B) or LV-mGDNF (C). Scale bar, 500 mm.
Figure 4. Number of motoneurons in mice injected with PBS, LV-LacZ,
LV-mGDNF, or LV-GDNF 30 (A, C) and 90 (B, D) d after transection of
the facial nerve. A, B, Nissl staining. C, D, ChAT immunostaining. Mo-
toneuron survival is expressed as the percentage of cells surviving on the
lesioned compared with the nonlesioned side. Only GDNF is statistically
different from PBS, LacZ, and mGDNF or untreated mice; ***p , 0.001.
Figure 5. Nissl stains of cross-sections through the facial nucleus from
lesioned animals injected with LV-GDNF (A, B) or LV-mGDNF (C, D)
90 d after nerve transection (Nissl staining). A, C, Nonlesioned side. B, D,
Lesioned side. Scale bar, 200 mm.
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number of transduced cells has been obtained previously in rat
striatum using a similar vector (Zufferey et al., 1997). Viral infec-
tion allows to stably express the transgene for up to at least 4
months. Only a mild inflammation consisting in minor perivascular
cuffing and in aggregation of lymphocytes around the injection
tract is observed. Both neurons and astrocytes are transduced, with
up to 45% of the SMI-32-positive facial motoneurons expressing
the reporter gene in the best experiments. In comparison, only
5–10% of the axotomized facial motoneurons express b-galac-
tosidase after injection of recombinant adenovirus into lesioned
nerves or facial muscles of neonatal rats (Baumgartner and
Shine, 1997; Gravel et al., 1997).
In contrast to nerve axotomy in other strains of adult mice and in
rats, which only results in the downregulation of a number of
proteins, including ChAT, the enzyme responsible for the synthesis
of the neurotransmitter acetylcholine (Lams et al., 1988; Yan et al.,
1994), facial nerve axotomy in 2-month-old Balb/C mice has been
shown to lead to 20–30% cell loss (Kou et al., 1995; Ferri et al.,
1998). In our hands, facial nerve lesion leads to the sustained loss
of as much as 60% of the motoneurons, probably because of the
older age of the mice at the time of the lesion (5 months). However,
the difference may also in part be attributable to our counting
method because we considered only clearly identifiable motoneu-
rons with a large soma diameter (;20 mm). Therefore, part of the
cells not included in our counts may have been counted by others.
In addition, some of the motoneurons that were not counted were
probably atrophic and not lost (Fig. 8).
Intraparenchymal delivery of the GDNF gene in adult Balb/C
mice leads to sustained expression and extensive diffusion of
GDNF within the brainstem. This viral gene delivery system thus
allows much better diffusion of the neurotrophic factor within the
brain parenchyma than intraventricular bolus injections of GDNF
(Lapchak et al., 1998). We also demonstrate that GDNF expres-
sion within and close to the facial nucleus allows to completely
protect facial motoneurons against axotomy-induced cell death
and/or atrophy, for as long as 3 months. Recombinant GDNF or
GDNF released by encapsulated genetically engineered cells ap-
plied in the vicinity of the cut nerve in neonatal rodents has also
been shown to be protective (Henderson et al., 1994; Zurn et al.,
1994; Oppenheim et al., 1995; Yan et al., 1995; Houenou et al.,
1996). However, only a transient, 1–2 week rescue could be ob-
tained (Vejsada et al., 1998). Protection lasting for 28 d was
obtained in neonatal rats by repeated application of GDNF at days
0 and 14 after axotomy. However, although rescue was complete at
14 d, it was only partial (40%) at 28 d (Matheson et al., 1997). In an
attempt to prolong the rescue period, adenoviral vectors have been
used recently to deliver neurotrophic factors either to denervated
muscles (Baumgartner and Shine, 1997; Gimenez y Ribotta et al.,
1997) or directly into the lesioned nerves (Gravel et al., 1997).
Although survival of axotomized motoneurons was maintained for
at least 5 weeks under those conditions (Gravel et al., 1997), only a
40–60% rescue was observed (Baumgartner and Shine, 1997;
Gimenez y Ribotta et al., 1997; Gravel et al., 1997). This may be
attributable to the fact that only 5–10% of the motoneurons were
transduced. In contrast, direct delivery and continuous expression
of GDNF via viral gene transfer within and surrounding the facial
motoneuron cell bodies leads to sustained and complete neuropro-
tection as evaluated both by Nissl staining and ChAT immunohis-
tochemistry. It is interesting to note that, despite the variation in
the number of motoneurons infected by the lentiviral vector, we
observe no correlation between the percentage of motoneurons
infected by LV-GDNF and the extent of rescue. Thus, GDNF
released by neurons and astrocytes at a distance can reach mo-
toneuron cell bodies of the facial nucleus and protect them against
degeneration. This indicates that both autocrine and paracrine
mechanisms are involved. Evidence for a paracrine mechanism of
action of GDNF has been obtained previously in neonatal rats in
which a larger number of motoneurons survived after facial nerve
axotomy than were transduced (Baumgartner and Shine, 1997;
Gravel et al., 1997). Upregulation of the signaling component
of the GDNF receptor c-ret and the ligand binding subunit
GDNFR-a has been described to occur after facial nerve lesion in
the rat (Burazin and Gundlach, 1998). Such increased expression,
combined with long-distance diffusion of GDNF and action both
via an autocrine and paracrine mechanism, may explain the effi-
cient neuroprotection obtained in adult Balb/C mice.
GDNF does not only protect facial motoneuron cell bodies
against cell death, but it also maintains the proximal processes of
these cells. This occurs despite the lack of target cell reinnervation
as evidenced by the absence of whisker movement on the lesioned
Figure 6. ChAT immunostaining of cross-sections through the facial nucleus from lesioned animals injected with LV-GDNF (A) and LV-LacZ ( B) 90 d
after nerve transection. Left, Nonlesioned side. Right, Lesioned side. Scale bar, 500 mm.
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side. In addition, GDNF also prevents atrophy and/or induces
hypertrophy in the lesioned motoneurons. Motoneuron hypertro-
phy has also been described to occur with GDNF after neonatal
motor nerve axotomy and ventral root avulsion (Henderson et al.,
1994; Li et al., 1995; Oppenheim et al., 1995). The mechanism for
this hypertrophy is unknown but may resemble the mechanism
observed with nerve growth factor on sympathetic and sensory
neurons (Levi-Montalcini, 1987).
Mice treated with GDNF show a sustained weight loss. This
effect appears to be specific to GDNF delivery close to the facial
nucleus, because intrastriatal and intranigral injection of identical
amounts of LV-GDNF in rat and mouse does not induce weight
loss (De´glon et al., 2000; data not shown). A 10–15% weight
reduction has been described previously to occur after intraven-
tricular injection of microgram quantities of GDNF (Lapchak et
al., 1997; Giehl et al., 1998). The mechanisms responsible for this
weight loss are unknown. It is possible that indirect activation of
higher brain centers involved in the control of feeding occurs in the
present study (Kupfermann, 1994).
In conclusion, the present report provides the first evidence that
continuous delivery of nanogram quantities of GDNF close to the
facial nucleus of adult mice via a lentiviral vector system can lead
to (1) sustained expression of the transgene, (2) extensive diffusion
of the molecule, and (3) complete and long-term protection of
motoneurons and their central processes against lesion-induced
cell death and atrophy. Delivery of trophic factors close to the
degenerating motoneuron cell bodies may be a prerequisite to
obtain significant neuroprotection in SOD transgenic mice, cur-
Figure 7. Central processes of facial motoneurons stained with anti-
neurofilament antibody (SMI-32). A, Nonlesioned, noninjected side. B,
Lesioned side injected with lenti-mutated GDNF. C, Lesioned side injected
with lenti-GDNF. Scale bar, 40 mm.
Figure 8. Effect of GDNF on the motoneuron size distribution 3 months
after the lesion. A–C, Size distribution (in square micrometers) of facial
motoneurons on the nonlesioned side: A, untreated; B, LacZ; and C,
GDNF. D–F, Soma size distribution on the lesioned side: D, Noninfected;
E, LacZ; and F, GDNF-infected animals.
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rently the best model of ALS (Gurney et al., 1994), as well as in
ALS patients, because application in the periphery has not given
any positive results so far.
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